Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

A Phase 2 Multi-Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Patients with advanced dry AMD with GA meeting inclusion criteria will be randomized in one eye in a 1:1:1 ratio comparing intravitreal high or low dose AAVCAGsCD59 with a sham injection. All enrolled subjects will be followed for 24 months to evaluate reduction in GA growth and safety of intravitreal AAVCAGsCD59.

Study Overview

• Status: Withdrawn
• Conditions: Geographic Atrophy; Dry Age-related Macular Degeneration; Gene Therapy; Intravitreal Injection
• Intervention / Treatment: Biological: Intravitreal AAVCAGsCD59; Other: Intravitreal Sham Injection

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Advanced dry AMD with GA in the study eye
2. BCVA in the study eye of 80 or less ETDRS letters (Snellen equivalent 20/25 or worse)
3. Total cumulative GA lesion size 2.5 mm2 to 12.5 mm2 in the study eye as confirmed by the reading center during the Screening Period.

Exclusion Criteria:

1. GA secondary to non-AMD etiologies in the study eye (i.e. myopia, inherited retinal diseases).
2. GA associated with the presence of an RPE rip.
3. GA contiguous with peripapillary atrophy.
4. Active CNV secondary to wet AMD in the study eye and currently receiving anti-VEGF ocular treatment within the previous 18 months.
5. Subretinal fibrosis in the macula from CNV both clinically and imaged on SD-OCT in the macula.
6. Previous macular laser photocoagulation (i.e. focal or grid laser for macular edema), photodynamic therapy (PDT), ocular/orbital radiation, laser to CNV, or subretinal surgery for CNV in the study eye.
7. History of conditions in the study eye which might alter visual acuity or interfere with study testing including proliferative diabetic retinopathy (PDR), clinically significant macular edema (CSME), central retinal vein occlusion (CRVO), hemi retinal vein occlusion (HRVO), macular branch retinal vein occlusion, and optic neuropathy.
8. Active uncontrolled glaucoma with at least one of the following: IOP>30 mmHg despite maximum medical treatment with glaucoma medications, cup-to-disc ratio of >0.9, visual field defects secondary to glaucoma that involve the macula, or optic atrophy from glaucoma.
9. Active acute or chronic infectious uveitis, retinitis, or conjunctivitis (excluding blepharitis)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection; Intravitreal AAVACGsCD59 at a dose of 1.071x10e12 vg administered once on Day 0	Biological: Intravitreal AAVCAGsCD59; AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye; Other Names: HMR59
Active Comparator: Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection; Intravitreal AAVACGsCD59 at a dose of 3.56x10e11 vg administered once on Day 0	Biological: Intravitreal AAVCAGsCD59; AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye; Other Names: HMR59
Sham Comparator: Sham Intravitreal Injection; Intravitreal Sham injection administered once on Day 0	Other: Intravitreal Sham Injection; Sham injection mimics a real injection in the enrolled eye; Other Names: Sham

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the change in Geographic Atrophy area (mm2) measured at Day 0 and compared to the measurement at Month 24	Geographic atrophy will be measured based on imaging of the retina	24 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of conversion from dry to wet age-related macular degeneration	Measure the number of treated eyes in the sham and AAVCAGsCD59-treated arms that convert from dry to wet age-related macular degeneration	24 Months
Change in visual acuity of the AAVCAGsCD59 treated eye	Visual acuity measured on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart will be compared at Day 0 and Month 24	24 Months

Collaborators and Investigators

• Sponsor: Hemera Biosciences

Study record dates

Study Major Dates

• Study Start (Anticipated): July 31, 2021
• Primary Completion (Anticipated): July 1, 2023
• Study Completion (Anticipated): September 1, 2023

Study Registration Dates

• First Submitted: March 22, 2020
• First Submitted That Met QC Criteria: April 20, 2020
• First Posted (Actual): April 24, 2020

Study Record Updates

• Last Update Posted (Actual): May 10, 2021
• Last Update Submitted That Met QC Criteria: May 6, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Retinal Degeneration; Retinal Diseases; Pathological Conditions, Anatomical; Macular Degeneration; Geographic Atrophy; Atrophy
• Other Study ID Numbers: HMR-2001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No